<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02280993</url>
  </required_header>
  <id_info>
    <org_study_id>Transplant BRaVE</org_study_id>
    <secondary_id>NL40688.018.12</secondary_id>
    <secondary_id>2012-003097-45</secondary_id>
    <nct_id>NCT02280993</nct_id>
  </id_info>
  <brief_title>Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients</brief_title>
  <official_title>Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse Who Are Eligible for High Dose Treatment Followed by Autologous Peripheral Blood Stem Cell Transplantation (ASCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marjolein Spiering</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Millennium: The Takeda Oncology Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To combine Brentuximab Vedotin with Dexamethasone, AraC and Cisplatin (DHAP) chemotherapy in&#xD;
      patients with Hodgkin lymphoma (HL) refractory to first line chemotherapy or in first relapse&#xD;
      is expected to induce a significantly higher (metabolic) complete remission (CR) rate prior&#xD;
      to consolidation with BEAM, as judged by FDG (18F-2-fluoro-2-deoxy-D-glucose&#xD;
      fluorodeoxyglucose)-PET negativity. This will be compared with published data on DHAP salvage&#xD;
      only. Increasing the metabolic CR rate prior to consolidation with high dose chemotherapy and&#xD;
      autologous stem cell transplantation (ASCT) is expected to improve progression free survival&#xD;
      (PFS) and overall survival (OS).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">May 2014</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>rate of patient with grade 4 Adverse Events</measure>
    <time_frame>12 weeks</time_frame>
    <description>The rate of patients with severe toxicity during cycle I-III of the combination treatment (BV + DHAP)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>(Severe) Adverse Event</measure>
    <time_frame>12 weeks</time_frame>
    <description>(Severe) Adverse Events during the combination treatment</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Response</measure>
    <time_frame>12 weeks</time_frame>
    <description>Metabolic CR rate (PET-CT) after the third cycle of BV-DHAP reinduction therapy</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Refractory</condition>
  <condition>Relapse</condition>
  <arm_group>
    <arm_group_label>DHAP-BV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brentuximab Vedotin with DHAP chemotherapy follow by Autologous Peripheral Blood Stem Cell Transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DHAP</intervention_name>
    <description>DHAP</description>
    <arm_group_label>DHAP-BV</arm_group_label>
    <other_name>Dexamethasone</other_name>
    <other_name>AraC</other_name>
    <other_name>Cisplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brentuximab Vedotin</intervention_name>
    <description>Brentuximab Vedotin</description>
    <arm_group_label>DHAP-BV</arm_group_label>
    <other_name>Adcetris</other_name>
    <other_name>SGN-35</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Autologous Peripheral Blood Stem Cell Transplantation</intervention_name>
    <description>Autologous Peripheral Blood Stem Cell Transplantation</description>
    <arm_group_label>DHAP-BV</arm_group_label>
    <other_name>ASCT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed CD30+ classical HL (central pathology review; results not&#xD;
             required to enroll the patient in the study), primarily refractory to first line&#xD;
             chemotherapy or in first relapse after any polychemotherapy regimen (e.g. ABVD&#xD;
             (Adriamycin, bleomycin, vinblastine, and dacarbazine), baseline BEACOPP ( bleomycin,&#xD;
             etoposide, Adriamycin, cyclophosphamide, Oncovin, procarbazine, and prednisone) or&#xD;
             escalated BEACOPP, or other induction regimens)&#xD;
&#xD;
          -  In case of relapse, the relapse must be histologically confirmed. In case histology is&#xD;
             not possible, at least confirmation of the relapse by fine-needle aspiration is&#xD;
             required.&#xD;
&#xD;
          -  Measurable disease, as defined in Appendix C i.e. CT scans showing at least 2 or more&#xD;
             clearly demarcated lesions with a long axis ≥ 1.5 cm and a short axis diameter ≥ 1.0&#xD;
             cm, or 1 clearly demarcated lesion with a long axis ≥ 2.0 cm and a short axis diameter&#xD;
             ≥ 1.0 cm. These lesions must be FDG (18F-2-fluoro-2-deoxy-D-glucose&#xD;
             fluorodeoxyglucose)-positive&#xD;
&#xD;
          -  Age ≥ 18 years (upper age limit for auto stem cell transplantation at the discretion&#xD;
             of the participating center)&#xD;
&#xD;
          -  WHO ≤ 2 (see appendix A)&#xD;
&#xD;
          -  Life expectancy of &gt; 3 months with treatment&#xD;
&#xD;
          -  No major organ dysfunction, unless HL-related&#xD;
&#xD;
          -  Total bilirubin &lt; 1.5x ULN (unless due to lymphoma involvement of the liver or a known&#xD;
             history of Gilbert's syndrome)&#xD;
&#xD;
          -  ALT/AST &lt; 3x ULN (unless due to lymphoma involvement of the liver; in that case&#xD;
             ALT/AST may be elevated up to 5 x ULN)&#xD;
&#xD;
          -  glomerular filtration rate (GFR) &gt; 60 ml/min as estimated by the Cockcroft&amp;Gault&#xD;
             formula (appendix D)&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1.5x109/L, unless caused by diffuse bone marrow&#xD;
             infiltration by the HL&#xD;
&#xD;
          -  Platelets ≥ 100x109/L, unless caused by diffuse bone marrow infiltration by the HL&#xD;
&#xD;
          -  Hemoglobin must be &gt;8 g/dL&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Able to adhere to the study visit schedule and other protocol requirements&#xD;
&#xD;
          -  Female patient is either post-menopausal for at least 1 year before the screening&#xD;
             visit or surgically sterile or if of childbearing potential, agrees to practice 2&#xD;
             effective methods of contraception, at the same time, from the time of signing the&#xD;
             informed consent through 30 days after the last dose of study drug, or agrees to&#xD;
             completely abstain from heterosexual intercourse.&#xD;
&#xD;
          -  Male patients, even if surgically sterilized, (i.e., status post vasectomy) agree to&#xD;
             practice effective barrier contraception during the entire study period and through 6&#xD;
             months after the last dose of study drug, or agrees to completely abstain from&#xD;
             heterosexual intercourse.&#xD;
&#xD;
          -  Eligible for high dose chemotherapy and autologous peripheral blood stem cell&#xD;
             transplantation&#xD;
&#xD;
          -  Resolution of toxicities from first-line therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Peripheral sensory or motor neuropathy grade ≥ 2&#xD;
&#xD;
          -  Known cerebral or meningeal disease (HL or any other etiology), including signs or&#xD;
             symptoms of progressive multifocal leukoencephalopathy&#xD;
&#xD;
          -  Symptomatic neurologic disease compromising normal activities of daily living or&#xD;
             requiring medications&#xD;
&#xD;
          -  Patients who have been using other investigational agents within at least 5 half lives&#xD;
             of the most recent agent used prior to enrollment in the study&#xD;
&#xD;
          -  Patients who were treated with myelosuppressive chemotherapy or biological therapy ≤ 4&#xD;
             weeks before study inclusion&#xD;
&#xD;
          -  Female patients who are both lactating and breast feeding or have a positive serum&#xD;
             pregnancy test during the screening period or a positive pregnancy test on Day 1&#xD;
             before first dose of study drug or adults of reproductive potential who are not using&#xD;
             effective birth control methods.&#xD;
&#xD;
          -  Patients with any active systemic viral, bacterial, or fungal infection requiring&#xD;
             systemic antibiotics within 2 weeks prior to first study drug dose&#xD;
&#xD;
          -  Patients who have a history of another primary malignancy less than 3 years before&#xD;
             study inclusion or previously diagnosed with another malignancy and have evidence of&#xD;
             residual disease, with the exception of non-melanoma skin cancer, completely resected&#xD;
             melanoma TNMpT1 and carcinoma in situ of the uterine cervix&#xD;
&#xD;
          -  Patients with known hypersensitivity to recombinant proteins, murine proteins, or to&#xD;
             any excipient contained in the drug formulation of brentuximab vedotin.&#xD;
&#xD;
          -  Patients with known HIV seropositivity, known hepatitis B surface antigen-positivity,&#xD;
             or known or suspected active hepatitis C infection&#xD;
&#xD;
          -  Patients receiving radiation therapy within 8 weeks prior to start of protocol&#xD;
             treatment. Emergency radiation therapy is allowed, as long as measurable disease (at&#xD;
             non-irradiated sites) persists.&#xD;
&#xD;
          -  Patients with a serious psychiatric disorder that could, in the investigator's&#xD;
             opinion, potentially interfere with the completion of treatment according to the&#xD;
             protocol&#xD;
&#xD;
               -  Patients who have any severe and/or uncontrolled medical condition or other&#xD;
                  conditions that could affect their participation in the study such as:Known&#xD;
                  history of symptomatic congestive heart failure (NYHA III, IV), myocardial&#xD;
                  infarction ≤ 6 months prior to first study drug&#xD;
&#xD;
               -  Evidence of current serious uncontrolled cardiac arrhythmia, angina pectoris,&#xD;
                  electrocardiographic evidence of acute ischemia or active conduction system&#xD;
                  abnormalities&#xD;
&#xD;
               -  Recent evidence (within 6 months before first dose of study drug) of a&#xD;
                  left-ventricular ejection fraction &lt;50%&#xD;
&#xD;
               -  severely impaired pulmonary function as defined as spirometry and DLCO (diffusing&#xD;
                  capacity of the lung for carbon monoxide) that is 50% or less of the normal&#xD;
                  predicted value and/or O2 saturation that is 90% or less at rest on room air&#xD;
&#xD;
               -  any active (acute or chronic) or uncontrolled infection/disorders that impair the&#xD;
                  ability to evaluate the patient or for the patient to complete the study&#xD;
&#xD;
          -  nonmalignant medical illnesses that are uncontrolled or whose control may be&#xD;
             jeopardized by this study drug, such as severe hypertension that is not controlled&#xD;
             with medical management and thyroid abnormalities when thyroid function cannot be&#xD;
             maintained in the normal range by medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anton Hagenbeek, PhD MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marie José Kersten, PhD MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marjolein Spiering, MSc</last_name>
    <role>Study Director</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier et Universitaire</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Free University Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Foundation Trust | Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Hospital, Manchester</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www2.hematologie-amc.nl/TransplantBRaVE_studie</url>
    <description>Transplant BRaVE</description>
  </link>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>August 19, 2014</study_first_submitted>
  <study_first_submitted_qc>October 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2014</study_first_posted>
  <last_update_submitted>March 12, 2018</last_update_submitted>
  <last_update_submitted_qc>March 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>Marjolein Spiering</investigator_full_name>
    <investigator_title>MSc</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Brentuximab Vedotin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

